The Small Molecule Screening and Synthesis Facility (SMSSF) provides UWCCC members with access to high throughput screening (HTS) instrumentation, chemical and RNAi libraries, synthetic chemistry, computational molecular modeling, virtual screening and expert staff. These are all critical activities for early stage discovery of new anti-cancer drugs. By providing infrastructure and expertise that is not available in individual member laboratories, the SMSSF enables UWCCC members to initiate and implement projects focused on the discovery and development of new anti-cancer agents, as well as the characterization of new drug targets. During the past five years, 50 members from seven of the eight Scientific Programs in the UWCCC have used the SMSSF for their research. The data generated at SMSSF has contributed to over 47 publications from UWCCC members and more than 40 funded grants. During the past five years the SMSSF successfully added three new services: screening of a human genome-wide RNAi library, synthetic chemistry for producing analogs or for scale-up and virtual screening.

Public Health Relevance

New safe and effective drugs are needed to treat human cancers. UWCCC members are able to initiate novel drug discovery projects because the Small Molecule Screening and Synthesis Facility provides access to infrastructure and expertise in drug discovery and to chemical and RNAi libraries that are not available in individual academic laboratories.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014520-40
Application #
8762770
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
40
Fiscal Year
2014
Total Cost
$120,671
Indirect Cost
$59,443
Name
University of Wisconsin Madison
Department
Type
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Goel, Shreya; Ferreira, Carolina A; Chen, Feng et al. (2018) Activatable Hybrid Nanotheranostics for Tetramodal Imaging and Synergistic Photothermal/Photodynamic Therapy. Adv Mater 30:
Wei, Weijun; Ehlerding, Emily B; Lan, Xiaoli et al. (2018) PET and SPECT imaging of melanoma: the state of the art. Eur J Nucl Med Mol Imaging 45:132-150
Yu, Bo; Wei, Hao; He, Qianjun et al. (2018) Efficient Uptake of 177 Lu-Porphyrin-PEG Nanocomplexes by Tumor Mitochondria for Multimodal-Imaging-Guided Combination Therapy. Angew Chem Int Ed Engl 57:218-222
Ehlerding, Emily B; Lacognata, Saige; Jiang, Dawei et al. (2018) Targeting angiogenesis for radioimmunotherapy with a 177Lu-labeled antibody. Eur J Nucl Med Mol Imaging 45:123-131
Shea, Michael P; O'Leary, Kathleen A; Wegner, Kyle A et al. (2018) High collagen density augments mTOR-dependent cancer stem cells in ER?+ mammary carcinomas, and increases mTOR-independent lung metastases. Cancer Lett 433:1-9
Conklin, Matthew W; Gangnon, Ronald E; Sprague, Brian L et al. (2018) Collagen Alignment as a Predictor of Recurrence after Ductal Carcinoma In Situ. Cancer Epidemiol Biomarkers Prev 27:138-145
Ko, Huaising C; Kimple, Randall J (2018) The Resident Individual Development Plan as a Guide for Radiation Oncology Mentorship. Int J Radiat Oncol Biol Phys 101:786-788
McDermott, Andrew J; Tumey, Tyler A; Huang, Mingwei et al. (2018) Inhaled Cryptococcus neoformans elicits allergic airway inflammation independent of Nuclear Factor Kappa B signalling in lung epithelial cells. Immunology 153:513-522
You, Xiaona; Kong, Guangyao; Ranheim, Erik A et al. (2018) Unique dependence on Sos1 in Kras G12D -induced leukemogenesis. Blood 132:2575-2579
Ferreira, Carolina A; Hernandez, Reinier; Yang, Yunan et al. (2018) ImmunoPET of CD146 in a Murine Hindlimb Ischemia Model. Mol Pharm 15:3434-3441

Showing the most recent 10 out of 1528 publications